Malaria vaccine trial for pregnant women launches in mali

NCT ID NCT05652504

Terminated Prevention Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 34 times

Summary

This Phase 1 trial in Mali will test the safety of the PfSPZ malaria vaccine in 400 healthy pregnant women aged 18-34. Participants will receive three injections of either the vaccine or a placebo. The study will monitor both mothers and their infants for up to a year after birth to check for any harmful effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PfSPZ vaccine (radiation-attenuated malaria sporozoites)
What this could lead to: If successful, this could show that the PfSPZ vaccine is safe for pregnant women, potentially leading to a way to protect them and their babies from malaria.
What could go wrong: This is an early Phase 1 safety trial, so it is not designed to prove the vaccine works. The study is currently suspended, and results may not show a clear safety benefit or may reveal unexpected risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA

Contacts and locations

Locations

Ou(SqrRoot)(Copyright)less(SqrRoot)(Copyright)bougou, Health Research Center

Ou(SqrRoot)(Copyright)less(SqrRoot)(Copyright)bougou, Mali

More trials for these conditions

Other studies related to the condition(s) this trial covers.